Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BB9 ACEs the HSC compartment.

Mervin C Yoder1

  • 1Indiana University School Of Medicine, USA.

Blood
|April 25, 2008
PubMed
Summary
This summary is machine-generated.

Researchers identified a new marker, monoclonal antibody BB9, to help isolate human hematopoietic stem cells. This antibody targets cells with stem and progenitor properties across human development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Diabetic Retinopathy with Human iPSC-Derived Vascular Reparative Cells in a Type 2 Diabetes Model.

Cells·2025
Same author

Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Tissue nanotransfection-based endothelial PLCγ2-targeted epigenetic gene editing rescues perfusion and diabetic ischemic wound healing.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Fully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency.

Cell stem cell·2024
Same author

Vasculogenic skin reprogramming requires TET-mediated gene demethylation in fibroblasts for rescuing impaired perfusion in diabetes.

Nature communications·2024
Same author

Thrombopoietic agents enhance bone healing in mice, rats, and pigs.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2024
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Area of Science:

  • Hematology
  • Immunology
  • Developmental Biology

Background:

  • Hematopoietic stem cells (HSCs) are crucial for blood formation and immune system development.
  • Identifying specific markers for HSCs is essential for research and therapeutic applications.
  • Current methods for HSC isolation face challenges in specificity and efficiency.

Discussion:

  • The monoclonal antibody BB9 has been identified as a novel marker for human HSCs.
  • BB9 reacts with hematopoietic cells exhibiting stem and progenitor characteristics.
  • This reactivity is observed throughout human ontogeny, suggesting broad applicability.

Key Insights:

  • Monoclonal antibody BB9 specifically identifies human hematopoietic stem and progenitor cells.
  • The antibody recognizes cells based on their morphologic, phenotypic, and functional properties.

Related Experiment Videos

  • BB9 demonstrates reactivity across the entire spectrum of human development.

    • Outlook:

    • BB9 offers a promising tool for the precise isolation of HSCs.
    • This discovery could advance stem cell research and regenerative medicine.
    • Further studies are warranted to explore BB9's full potential in clinical settings.